Shots:

• Novartis to get an option on Iconic’s ophthalmology program in exchange for an up front payment and equity investment in Iconic
• Iconic is evaluating its anti-Tissue Factor monoclonal antibody- ICON-4 for the treatment of age-related macular degeneration and plans the onset of clinical studies in 2020
• Iconic Therapeutics targets Tissue Factor biology to develop new therapies that bind to and antagonize Tissue factor in retinal diseases- cancer and other diseases where Tissue Factor is overexpressed

Click here to­ read full press release/ article | Ref: Iconic Therapeutics | Image: Elmvc